An interventional study of Cocoa extract and Cocoa extract placebo in Migraine, sponsored by Brigham and Women's Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 697 studies in Migraine Disorders with a site in United States — 92 open to participants now, 114 under way, 27 of them phase 3. Migraine Disorders · United States.
Among the 697 studies in Migraine Disorders with a site in United States, this one is the 256th largest by planned enrollment of the 610 interventional ones that give a count, is one of 32 that started in 2025, is one of 204 with no phase, reaches primary completion later than 24 of the 113 other live ones, and was the 636th registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →92 of the 697 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:
Salvia BioElectronics · Sites in United States
Ages 22–84
University of Colorado, Denver · Sites in United States
Ages 12–17
Columbia University · Sites in United States
Ages 18–55
TriGemX Bio, Inc. · Sites in United States
Ages 18–75
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
697 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 113 · Phase 3 151 · Phase 4 101
First in 1999; this study’s year is marked. 32 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 114 is above the median of 80 across 1,271 interventional studies indexed under Migraine Disorders.
Median enrollment 78 across the 610 interventional studies, 195 across the 84 observational. Of the 528 that completed or were terminated, 305 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
345 of 697 have an industry lead sponsor. The 10 most frequent:
Brigham and Women's Hospital is the lead sponsor of 1,270 studies on the registry; 230 are open to participants now.
Of its 117 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.
Brigham and Women's Hospital has 8 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
47 of the studies in Migraine Disorders with a site in United States that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07645924Phase 3TriGemX Bio, Inc.A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | 2027-02 |
| NCT05598723Phase 3Naval Medical Center Camp LejeuneBOTOX® vs. XEOMIN® for Chronic Migraine | 2027-02-24 |
| NCT07018700Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine | 2027-03 |
| NCT07018713Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | 2027-03 |
Add all 47 to your calendar (.ics) → With an account.
Among the 697 studies in Migraine Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to assess the feasibility of recruitment and adherence to a high-dose cocoa extract supplement in individuals diagnosed with migraine. The main questions it aims to answer are:
Researchers will compare two doses of cocoa extract to placebo to determine the acceptability of higher doses of cocoa extract supplementation in this patient population.
Participants will be asked to:
The criteria were revised on the registry on Oct 29, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Self-reported clinician diagnosis of migraine with or without aura which does not meet criteria for chronic migraine (according to the International Classification of Headache Disorders 3rd edition)
Completion of at least 22 headache diary days during the 28 day run-in period
o Report migraine frequency between 4 to 14 days during the 28 day run-in period
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to this arm will take four placebo pills per day.
Dietary Supplement: Cocoa extract placebo
Participants assigned to this arm will take two 250 mg cocoa extract pills per day and two placebo pills per day
Dietary Supplement: Cocoa extract
Participants assigned to this arm will take four 250 mg cocoa extract pills per day
Dietary Supplement: Cocoa extract
Cocoa extract manufactured as 250 mg capsules
Cocoa extract placebo
Recruitment
We will be able to recruit and randomize 114 eligible individuals
Time frame: 15 months
Retention
Retention will be quantified by the proportion of subjects who record their migraines for at least 22 out of 28 days during run-in and the last four weeks of the intervention and complete all questionnaires at baseline and follow-up
Time frame: From run-in to end of treatment at 12 weeks
Adherence
Adherence will be calculated as the proportion of participants who miss no more than 12 days of study pills (i.e. participants will consume study pills on 85% of the intervention days)
Time frame: 12 week intervention period
Migraine days
Number of migraine attacks as recorded in migraine diaries
Time frame: Four week run-in period and final four weeks of the 12 week intervention period
Responder rate
Proportion of individuals who experience a ≥50% reduction in migraine days
Time frame: Four week run-in period and final four weeks of the 12 week intervention period
Migraine severity
Four-point scale with categories of "absent, mild, moderate, or severe".
Time frame: Four week run-in period and final four weeks of the 12 week intervention period
Adverse events
Potential side effects and adverse events
Time frame: 12 week intervention period
Reports of worsening of migraine symptoms
Worsening of photophobia, phonophobia, or osmophobia, and worsening of aura symptoms in the past week compared to the week prior
Time frame: 12 week intervention period
Allodynia Symptom Checklist
Survey assessing how often individuals with migraine experience allodynia
Time frame: Baseline and end of the 12 week intervention period
Migraine Disability Assessment Test (MIDAS)
Evaluates the impact headaches have on a patient's life
Time frame: Baseline and end of the 12 week intervention period
PROMIS-29
Measures of patient-reported health status for physical, mental, and social well-being
Time frame: Baseline and end of the 12 week intervention period
Urine levels of gamma-valerolactone metabolites (gVLM)
Biomarker of dietary flavanol intake
Time frame: Four week run-in period and final four weeks of the 12 week intervention period
Plan to share: Yes — Cleaned, item-level spreadsheet data for all variables will be shared openly, along with example quantifications and transformations from initial raw data
Supporting information: Analytic code
Time frame: Data will be shared no later than time of the final publication of study results or the end of the performance period, whichever comes first. The duration of preservation and sharing of the data will be a minimum of 10 years after the end of the funding period.
Access criteria: Data and supporting materials will be shared on the Harvard Dataverse. The data that is shared will be shared by unrestricted download.
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Feb 2027, 19 months after the start.
Of 310 non-industry interventional studies with no phase under Migraine Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 19 months is above that.
Counting every sponsor, half of 360 studies reached it within 15 months; a quarter within 7 and three quarters within 33.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Dec 2026 → Feb 2027 and completion Dec 2026 → Feb 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cocoa bean
Brigham and Women's Hospital →